Postradiation MR Imaging Features in Molecular and Mutational Analyses in Pontine Pediatric Diffuse Midline Gliomas.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
BACKGROUND AND PURPOSE: We aimed to describe the postradiation imaging features in children with pontine pediatric diffuse midline glioma, and to identify associations between these changes and histone mutational status, as well as overall survival. MATERIALS AND METHODS: Patients were recruited as part of an institutional review board-approved, multicenter clinical trial: Molecularly Determined Treatment of Diffuse Intrinsic Pontine Glioma. Subjects had baseline MR imaging that showed classic imaging criteria of pontine diffuse midline glioma and postradiation imaging at regular intervals. All patients underwent biopsy before therapy initiation and received standard radiation therapy with adjuvant bevacizumab. Patients were subsequently stratified based on methylation status and epidermal growth factor receptor expression in the biopsy specimen. Imaging analyses included postradiation T2/FLAIR and enhancing tumor volumes, as well as normalized ADC (nADC) histogram metrics (mean, median, mode, skewness, and kurtosis) at 2 and 4 months postradiation. The mutation subgroups were compared by using a Wilcoxon rank-sum test. RESULTS: Forty-one patients met eligibility criteria, and mutational status was identified in 35. The median age was 6 years (range: 1.2-17). Seventeen of 35 (49%) had H3-3A histone mutations, 10 of 35 (29%) had H3C2/3, and 8 of 35 (22%) were wild-type (WT). Except for enhancing volume at postradiation time point 2 (4 months postradiation; RT2), all imaging features had a statistically significant change (P < .05) from baseline to time point 1 (2 months postradiation; RT1) and RT2. Within the cohort of patients that had H3-mutant tumors (n = 27), patients with H3C2/3 had statistically significantly higher mean nADC_FLAIR (P = .05), mode nADC_FLAIR (P = .003), median nADC_FLAIR (P = .02), and mode nADC-enhancement (P = .04) than patients with H3-3A at RT1. These nADC histogram metrics were not statistically significantly different at RT2. Moreover, we found no statistically significant difference in ADC histogram metrics postradiation, when we compared H3-mutant versus WT tumors. CONCLUSIONS: Postradiation MR imaging features are differentially correlated with the underlying mutational status of pediatric pontine diffuse midline glioma.